The announcement of an exclusive worldwide license agreement with Aexon Labs positions NLS Pharmaceutics favorably in the biotech and pharmaceuticals market. This deal not only enhances NLSP's product portfolio but also signals potential future revenue growth from the development and commercialization of the Dual Orexin Receptor Agonists platform. Investors are likely to view this agreement positively, leading to a short-term increase in NLSP's stock price.